Biofidus
- Company typePrivate
- Founded2015
- HeadquartersBielefeld, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
Biofidus firmographics
Firmographics- Name
- Biofidus
- Legal name
- Biofidus AG
- Website
- https://biofidus.de
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biofidus industry classification
Industry- Product category
- Contract Research / Bioanalytical Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
- akta.pro secondary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Biofidus is headquartered
LocationHeadquarters
- HQ city
- Bielefeld
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Biofidus business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- CRO Analytical Services: Contract research organization providing fee-for-service analytical testing and characterization studies for biopharmaceutical clients. Revenue generated through project-based engagements for structural and functional analysis of biologics, biosimilars, and cell/gene therapies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Biofidus product offering
Product offeringCore offering
Biofidus is a contract research organization (CRO) providing fee-for-service bioanalytical testing and characterization studies for biopharmaceutical clients. The company delivers a holistic analytical platform covering 150+ services across four pillars — Studies (biosimilar, developability, stability, lead/clone selection), Biologics (antibody, multispecific, ADC, nanobody, fusion protein, peptide/hormone, AAV/CGT characterization), Popular Analytical Services (protein sequencing, SPR, cell-based assays, glycosylation, CE, aggregation, higher order structure, impurity analysis), and Small Molecules (spent media, neurotransmitter, metabolite, vitamin analysis). Services target pharmaceutical and biotechnology companies developing New Biological Entities, biosimilars, and cell and gene therapies from early-stage R&D through regulatory submission.
Product overview
Biofidus is a Contract Research Organization (CRO) offering a holistic analytical service platform spanning from discovery to commercialization. The company provides integrated service modules organized into four main categories: Studies (Biosimilar Studies, Developability Studies, Stability Studies, Lead and Clone Selection), Biologics (Antibody Characterization, Multispecific Antibodies, Nanobodies, ADC Analysis, Fusion Proteins, Enzymes, Peptides and Hormones, AAV and CGT Services), Popular Analytical Services (including Protein Sequencing, SPR Analysis, Cell-Based Assays, Bioactivity Studies, Glycosylation Analysis, and more), and Small Molecules (Spent Media, Neurotransmitter, Metabolites, Vitamins). The platform is designed to support New Biological Entities (NBEs) and biosimilars development, providing comprehensive structural and functional characterization from early analytics through robust data packages for regulatory submission.
Differentiator
Problem solved
Functional benefit
Products and services
- Studies Service Line Project-based analytical study packages for biologics and biosimilar development, including biosimilar comparability studies, developability assessment, forced degradation and stability studies, and lead candidate and cell clone selection. Targeted at pharmaceutical and biotech sponsors progressing NBEs and biosimilars through early and late development.
- Biologics Characterization Service Line Analytical characterization services organized by therapeutic modality, including IgG and multispecific antibody characterization, antibody-drug conjugate (ADC) analysis, nanobody characterization, enzyme characterization, fusion protein analysis, peptide and hormone analysis, and AAV and cell and gene therapy (CGT) vector analysis. Aimed at sponsors developing complex biologics across multiple modalities.
- Popular Analytical Services Individual analytical assays available as standalone service modules: protein sequencing (N-terminal and full-length), SPR analysis for binding kinetics, cell-based assays, bioactivity studies, amino acid modifications and PTM analysis, glycosylation analysis, capillary electrophoresis (CE) analysis, aggregation analysis, charge heterogeneity analysis, DNA/RNA sequencing, higher order structure characterization, impurity analysis, and serum and plasma assays for PK/PD studies. Individual assays can be contracted per project for biologics characterization and regulatory data packages.
- Small Molecules Analytical Services Small-molecule analytical services including spent media analysis (cell culture media components and metabolites for bioprocess optimization), neurotransmitter quantification, metabolite identification and quantification in biological systems, and vitamin analysis for quantification and characterization across matrices. Targeted at sponsors requiring complementary small-molecule analytics alongside biologics work.
Quantifiable outcome
- 1000+ projects completed
- +3 more outcomes
Companies that use Biofidus
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Biofidus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Biofidus partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Midas PharmacoreStrategic merger combining Biofidus' deep analytical expertise with Midas Pharma's broad regulatory and commercialization capabilities. Together they provide seamless support across the full product lifecycle from early development through commercialization. This partnership enhances the holistic analytical platform with regulatory guidance and commercialization support.
- Evitria AGminorJoint scientific collaboration resulting in published workflow for ADCC-enhanced antibody development. The publication 'Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development' demonstrates co-development of analytical methods for antibody-dependent cellular cytotoxicity enhancement.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Biofidus competitors and assessment
Company assessmentBroad incumbents
- Intertek Pharmaceutical Services: Global testing and quality assurance provider with bioanalytical and biologics characterization services supporting pharma development and release. Competes for outsourced analytical and stability work.
- SGS Health Sciences: Global testing, inspection, and certification company with a health sciences division providing bioanalytical, biopharma, and clinical trial services. Competes for biologics characterization and biosimilar analytical work.
- WuXi Biologics: Global biologics CDMO/CRO offering bioanalytical, characterization, and biosimilar development services at very large scale. Competes on capacity and integrated end-to-end biologics offerings.
- Charles River Laboratories: Major CRO with broad biopharma services including bioanalytical, biologics characterization, and biosafety testing. Competes with Biofidus for outsourced analytical work from large pharma and biotech clients.
- Sartorius (BIA Separations): Bioprocessing and analytics provider offering chromatography-based analytical solutions for biologics and gene therapies. Adjacent competitor in analytics and purification characterization for complex biologics.
- Eurofins Bioanalytical Services: Global laboratory services group with a large bioanalytical and biopharma product testing business serving pharma and biotech across drug development. Competes on scale, geographic reach, and integrated service breadth.
Emerging players
- Bio-Techne: Reagents, assays, and analytical tools provider for protein and cell-based research. Overlaps with Biofidus in protein characterization workflows and competes in the same research customer base.
Direct peers
- Protagen Protein Services: Specialist bioanalytical CRO focused on protein characterization, biosimilar comparability, and biologics analytics. Direct competitor to Biofidus in the same German/European specialty bioanalytical niche.
- Interpharma Praha (Bioanalytical): European bioanalytical CRO providing PK/PD, immunogenicity, and biologics characterization services. Direct peer in the regional specialty bioanalytical CRO market served by Biofidus.
Regional players
- Selvita: Central European CRO with bioanalytical and drug discovery services. Comparable in size and positioning as a regionally focused, science-led CRO serving pharma and biotech clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Biofidus social profiles
Digital presenceBiofidus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biofidus leadership team
Management profileNumber of profiles
Profiles8 records
Biofidus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biofidus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biofidus
What does Biofidus do?
Biofidus is a contract research organization (CRO) providing fee-for-service bioanalytical testing and characterization studies for biopharmaceutical clients. The company delivers a holistic analytical platform covering 150+ services across four pillars — Studies (biosimilar, developability, stability, lead/clone selection), Biologics (antibody, multispecific, ADC, nanobody, fusion protein, peptide/hormone, AAV/CGT characterization), Popular Analytical Services (protein sequencing, SPR, cell-based assays, glycosylation, CE, aggregation, higher order structure, impurity analysis), and Small Molecules (spent media, neurotransmitter, metabolite, vitamin analysis). Services target pharmaceutical and biotechnology companies developing New Biological Entities, biosimilars, and cell and gene therapies from early-stage R&D through regulatory submission.
Is Biofidus a public or private company?
Biofidus is a private company. It is classified as family owned and is currently operating.
When was Biofidus founded?
Biofidus was founded in 2015. It employs 11 to 50 people.
Where is Biofidus based?
Biofidus is headquartered in Bielefeld, Germany, in the Europe region.
How does Biofidus make money?
One revenue line is on record: CRO Analytical Services.
Who are Biofidus's main competitors?
Broad incumbents on record are Intertek Pharmaceutical Services, SGS Health Sciences, WuXi Biologics, Charles River Laboratories, Sartorius (BIA Separations) and Eurofins Bioanalytical Services. Bio-Techne is listed as an emerging player. Direct peers are Protagen Protein Services and Interpharma Praha (Bioanalytical). Selvita is listed as a regional player.
Does Biofidus have an API?
No public API is recorded for Biofidus.
What industry is Biofidus in?
Biofidus's product category is Contract Research / Bioanalytical Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 8731.